Cargando…
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial
IMPORTANCE: There are no medical interventions for the orphan disease CYLD cutaneous syndrome (CCS). Transcriptomic profiling of CCS skin tumors previously highlighted tropomyosin receptor kinases (TRKs) as candidate therapeutic targets. OBJECTIVE: To investigate if topical targeting of TRK with an...
Autores principales: | Danilenko, Marina, Stamp, Elaine, Stocken, Deborah D., Husain, Akhtar, Zangarini, Monique, Cranston, Amy, Stones, Robert, Sinclair, Naomi, Hodgson, Kirsty, Bowett, Susan A., Roblin, David, Traversa, Silvio, Plummer, Ruth, Veal, Gareth, Langtry, James A. A., Ashworth, Alan, Burn, John, Rajan, Neil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128505/ https://www.ncbi.nlm.nih.gov/pubmed/29955768 http://dx.doi.org/10.1001/jamadermatol.2018.1610 |
Ejemplares similares
-
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial
por: Cranston, Amy, et al.
Publicado: (2017) -
Development and validation of LC–MS/MS with in-source collision-induced dissociation for the quantification of pegcantratinib in human skin tumors
por: Zangarini, Monique, et al.
Publicado: (2017) -
Diverse assays from a single skin punch biopsy to assess topical drug intervention
por: Danilenko, M., et al.
Publicado: (2019) -
Inherited pulmonary cylindromas: extending the phenotype of CYLD mutation carriers
por: Brown, S.M., et al.
Publicado: (2018) -
Dysregulated TRK Signalling is a Therapeutic Target in CYLD Defective Tumours
por: Rajan, Neil, et al.
Publicado: (2011)